Trial · NCT00489918
Results by group25
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 25
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in Lumbar Spine Bone Mineral Density (BMD): Baseline to Week 24 | Macroflux® Placebo | -0.33 | Standard Deviation 3.467 | percent change | |
| Percent Change in Lumbar Spine Bone Mineral Density (BMD): Baseline to Week 24 | Macroflux® 20 mcg | 2.96 | Standard Deviation 3.524 | percent change | |
| Percent Change in Lumbar Spine Bone Mineral Density (BMD): Baseline to Week 24 | Macroflux® 30 mcg | 3.47 | Standard Deviation 3.575 | percent change | |
| Percent Change in Lumbar Spine Bone Mineral Density (BMD): Baseline to Week 24 | Macroflux® 40 mcg | 4.97 | Standard Deviation 4.114 | percent change | |
| Percent Change in Lumbar Spine Bone Mineral Density (BMD): Baseline to Week 24 | FORTEO® | 3.55 | Standard Deviation 3.730 | percent change | |
| Percent Change in Lumbar Spine Bone Mineral Density: Baseline to Week 12 | Macroflux® Placebo | 0.97 | Standard Deviation 3.312 | Percent change | |
| Percent Change in Lumbar Spine Bone Mineral Density: Baseline to Week 12 | Macroflux® 20 mcg | 1.55 | Standard Deviation 2.606 | Percent change | |
| Percent Change in Lumbar Spine Bone Mineral Density: Baseline to Week 12 | Macroflux® 30 mcg | 2.04 | Standard Deviation 3.277 | Percent change | |
| Percent Change in Lumbar Spine Bone Mineral Density: Baseline to Week 12 | Macroflux® 40 mcg | 2.5 | Standard Deviation 2.86 | Percent change | |
| Percent Change in Lumbar Spine Bone Mineral Density: Baseline to Week 12 | FORTEO® | 2.81 | Standard Deviation 2.771 | Percent change | |
| Absolute Change in Lumbar Spine BMD: Baseline to Week 12 | Macroflux® Placebo | 0.007 | Standard Deviation 0.0234 | g/cm^2 | |
| Absolute Change in Lumbar Spine BMD: Baseline to Week 12 | Macroflux® 20 mcg | 0.011 | Standard Deviation 0.0191 | g/cm^2 | |
| Absolute Change in Lumbar Spine BMD: Baseline to Week 12 | Macroflux® 30 mcg | 0.014 | Standard Deviation 0.0238 | g/cm^2 | |
| Absolute Change in Lumbar Spine BMD: Baseline to Week 12 | Macroflux® 40 mcg | 0.017 | Standard Deviation 0.0285 | g/cm^2 | |
| Absolute Change in Lumbar Spine BMD: Baseline to Week 12 | FORTEO® | 0.021 | Standard Deviation 0.0201 | g/cm^2 | |
| Percent Change in Total Hip Bone Mineral Density: Baseline to Week 24 | Macroflux® Placebo | -0.634 | Standard Deviation 1.9719 | Percent change | |
| Percent Change in Total Hip Bone Mineral Density: Baseline to Week 24 | Macroflux® 20 mcg | 0.138 | Standard Deviation 2.0386 | Percent change | |
| Percent Change in Total Hip Bone Mineral Density: Baseline to Week 24 | Macroflux® 30 mcg | 0.553 | Standard Deviation 2.3694 | Percent change | |
| Percent Change in Total Hip Bone Mineral Density: Baseline to Week 24 | Macroflux® 40 mcg | 1.331 | Standard Deviation 2.1111 | Percent change | |
| Percent Change in Total Hip Bone Mineral Density: Baseline to Week 24 | FORTEO® | 0.094 | Standard Deviation 2.6194 | Percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00489918/results